Search Results for 'Phase I'
Contract Service Directory Companies
Microsite Companies
Featured Companies
View All Buyers Guide Companies »
Contract Service Directory Categories
View All Categories »
-
Bio News | Clinical Trials | Drug Development | Drug Discovery | Industry News | R&D | Trials & Filings
Denali Announces Positive Phase I Study Results
The study involved DNL201, a small molecule inhibitor of leucine-rich repeat kinase 208.03.18
-
Bio News | Drug Development | Drug Discovery | Industry News
-
Biosimilars | Drug Development | Trials & Filings
Sandoz Phase I Biosimilar Achieves Positive Results
Proposed biosimilar to Neulasta demonstrates PK, PD, safety and efficacy12.08.17
-
Bio News | Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines | Breaking News | Clinical Trial Materials | Clinical Trials | Collaborations & Alliances | Industry News
Cobra Biologics Helps Alligator Bio Complete Phase I Trial
maxXpress platform used to enable rapid and high-yielding expression of protein ADC-101304.12.17
-
APIs | Clinical Trial Materials | Clinical Trials | Drug Development | Formulation Development
Choosing Oral Formulations for First-in-man Clinical Trials
Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seemsJon Sutch, Senior Manager of Formulation Development, Patheon 10.11.16
-
Breaking News | Clinical Trials | CRO News | Drug Development | GMPs/GCPs
-
Phase I
Initial safety studies in humans. May include as few as 10 subjects, often in healthy volunteers, and includes PK, ADME/T and dose escalation studies to determine some side effects. Usually open label.…02.27.12
-
Breaking News | Trials & Filings
Array Starts Phase I for p38 Drug
Array BioPharma has filed an Investigational New Drug (IND) application for ARRY-614 with the FDA and has initiated a Phase 1 clinical trial. ARRY-614, a potent, orally active p38 / Tie2 inhibitor, has shown good efficacy and a low side effect profil…03.25.08
